Mindblown: a blog about philosophy.
-
The Power of Actionable Early Lung Cancer Detection | Biodesix
As we mark Lung Cancer Awareness Month, the spotlight illuminates a difficult reality – lung cancer remains one of the most prevalent and lethal cancers worldwide. However, even among these daunting statistics, there are glimmers of hope. One that Biodesix is deeply committed to amplifying: The power of actionable early detection.
-
Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting
Studies highlight the clinical utility and real-world impact of the Nodify CDT® and Nodify XL2® tests in managing both benign and malignant pulmonary nodules.
-
Celebrating Cabrini Day: A Reflection on Service, Community, and Purpose
As we approach Cabrini Day, a state holiday unique to Colorado, I find myself reflecting on the significance of this day for our team at Biodesix and the broader community. While the holiday’s roots are geographically tied to our home state, the values it represents resonate deeply with our mission and vision.
-
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
New data highlights two novel proteomic tests that support treatment decision making in patients with non-small cell lung cancer (NSCLC):
-
Biodesix to Participate in Two Upcoming Investor Conferences in September
September 5, 2023 at 6:00 AM EDT
-
Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer
Data demonstrates a 51% relative increase in the proportion of lung nodule biopsies diagnosing cancer
-
Biodesix Announces Second Quarter 2023 Results and Highlights
August 7, 2023 at 4:01 PM EDT
-
Biodesix Participates in Canaccord Genuity Annual Growth Conference
BOULDER, Colo.–(BUSINESS WIRE)– Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1×1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, which will be held from August 7-10, 2023.
-
Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023
July 24, 2023 at 6:00 AM EDT | Download PDF
-
Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules
Download PDF
Got any book recommendations?